A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

NCT02174172 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Cancers

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: Interferon alfa-2b
DRUG: Ipilimumab
DRUG: Obinutuzumab
DRUG: PEG-interferon alfa-2a

Sponsor

Hoffmann-La Roche